A Phase 1/2a, Open-Label, Dose-Escalation, Dose-Expansion, Parallel Assignment Study to Evaluate the Safety and Clinical Activity of PBCAR0191 in Subjects with Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemi
MD Anderson Study Status
This is a Phase 1/2a, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-optimization study to evaluate the safety and clinical activity of PBCAR0191 in adults with r/r B ALL (Cohort A) and in adults with r/r B-cell NHL (Cohort N) and identify a treatment regimen most likely to result in clinical efficacy while maintaining a favorable safety profile.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia
For general questions about clinical trials: